Biotech · Private company
NGM Biopharmaceuticals, Inc
Track this companyFree. Adds NGM Biopharmaceuticals, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials161 recruiting or active
Pipeline programs25From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline25
- aldaferminPhase 2 · Compensated CirrhosisClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 100mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 100mg Q3WPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 100mg with Gemcitabine and AbraxanePhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 30mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 30mg with Gemcitabine and AbraxanePhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 Q4WPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM120 Q8WPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM282Phase 2 · Primary Sclerosing CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- NGM282Phase 2 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- NGM282Phase 2 · Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov · fetched Nov 12, 2026
- NGM621Phase 2 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- NGM707Phase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- NGM707 plus pembrolizumab (KEYTRUDA®)Phase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- Sham ComparatorPhase 2 · Geographic AtrophyClinicalTrials.gov · fetched Nov 12, 2026
- AldaferminPhase 1 · Impaired Hepatic FunctionClinicalTrials.gov · fetched Nov 12, 2026
- AldaferminPhase 1 · Healthy MaleClinicalTrials.gov · fetched Nov 12, 2026
- Aldafermin (NGM282)Phase 1 · Impaired Renal FunctionClinicalTrials.gov · fetched Nov 12, 2026
- NGM313Phase 1 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
- NGM438Phase 1 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM831Phase 1 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)Phase 1 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGM831 plus pembrolizumab (KEYTRUDA®)Phase 1 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA ®)Phase 1 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- PioglitazonePhase 1 · ObeseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.PHASE2 · RECRUITING · started Jun 25, 2025ClinicalTrials.gov NCT07033026 · fetched Nov 12, 2026
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsPHASE1 · UNKNOWN · started May 11, 2022ClinicalTrials.gov NCT05311618 · fetched Nov 12, 2026
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsPHASE1 · UNKNOWN · started Mar 31, 2022ClinicalTrials.gov NCT05215574 · fetched Nov 12, 2026
- Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)PHASE2 · COMPLETED · started Dec 1, 2021ClinicalTrials.gov NCT05130047 · fetched Nov 12, 2026
- Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesPHASE1_PHASE2 · UNKNOWN · started Jun 9, 2021ClinicalTrials.gov NCT04913337 · fetched Nov 12, 2026
- Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese SubjectsPHASE1 · COMPLETED · started Apr 13, 2021ClinicalTrials.gov NCT04828265 · fetched Nov 12, 2026
- Study of Aldafermin (NGM282) in Participants With Impaired Hepatic FunctionPHASE1 · COMPLETED · started Apr 1, 2021ClinicalTrials.gov NCT04823702 · fetched Nov 12, 2026
- A Study of NGM621 in Participants With Geographic AtrophyPHASE2 · COMPLETED · started Jul 22, 2020ClinicalTrials.gov NCT04465955 · fetched Nov 12, 2026
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)PHASE2 · COMPLETED · started Mar 23, 2020ClinicalTrials.gov NCT04210245 · fetched Nov 12, 2026
- Study of Aldafermin (NGM282) in Participants With Impaired Renal FunctionPHASE1 · COMPLETED · started Nov 8, 2019ClinicalTrials.gov NCT04179630 · fetched Nov 12, 2026
- Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyPHASE1_PHASE2 · COMPLETED · started Oct 16, 2019ClinicalTrials.gov NCT04068896 · fetched Nov 12, 2026
- Study of NGM621 in Participants With Geographic AtrophyPHASE1 · COMPLETED · started Jul 26, 2019ClinicalTrials.gov NCT04014777 · fetched Nov 12, 2026
- Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)PHASE2 · COMPLETED · started May 16, 2019ClinicalTrials.gov NCT03912532 · fetched Nov 12, 2026
- Study of NGM313 in Obese ParticipantsPHASE1 · COMPLETED · started Sep 11, 2017ClinicalTrials.gov NCT03298464 · fetched Nov 12, 2026
- A Study of NGM282 in Patients With Primary Sclerosing CholangitisPHASE2 · COMPLETED · started Mar 1, 2016ClinicalTrials.gov NCT02704364 · fetched Nov 12, 2026
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Jul 31, 2015ClinicalTrials.gov NCT02443116 · fetched Nov 12, 2026